131 related articles for article (PubMed ID: 16585011)
21. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Brand R; Apperley J; Crawley C; Ruutu T; Corradini P; Carreras E; Devergie A; Guglielmi C; Kolb HJ; Niederwieser D;
Haematologica; 2006 Apr; 91(4):513-21. PubMed ID: 16533723
[TBL] [Abstract][Full Text] [Related]
22. Effects of race on survival after stem cell transplantation.
Mielcarek M; Gooley T; Martin PJ; Chauncey TR; Young BA; Storb R; Torok-Storb B
Biol Blood Marrow Transplant; 2005 Mar; 11(3):231-9. PubMed ID: 15744242
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
24. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
25. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
26. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
27. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
[TBL] [Abstract][Full Text] [Related]
28. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Kantarjian H; O'Brien S; Cortes J; Giles F; Thomas D; Kornblau S; Shan J; Beth Rios M; Keating M; Freireich E; Talpaz M
Cancer; 2003 Jul; 98(1):81-5. PubMed ID: 12833459
[TBL] [Abstract][Full Text] [Related]
29. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
[TBL] [Abstract][Full Text] [Related]
30. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
31. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
Goldman J
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
34. Chronic myelogenous leukaemia (CML): an update.
Kumar L
Natl Med J India; 2006; 19(5):255-63. PubMed ID: 17203680
[TBL] [Abstract][Full Text] [Related]
35. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
[TBL] [Abstract][Full Text] [Related]
36. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
37. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
Burke MJ; Willert J; Desai S; Kadota R
Pediatr Blood Cancer; 2009 Dec; 53(6):992-5. PubMed ID: 19621426
[TBL] [Abstract][Full Text] [Related]
38. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
39. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]